Phase II study of sunitinib in men with advanced prostate cancer. [electronic resource]
Producer: 20090602Description: 913-20 p. digitalISSN:- 1569-8041
- Adenocarcinoma -- blood
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- adverse effects
- Angiogenic Proteins -- blood
- Antineoplastic Agents, Phytogenic -- therapeutic use
- Docetaxel
- Drug Resistance, Neoplasm
- Humans
- Indoles -- adverse effects
- Male
- Middle Aged
- Prostate-Specific Antigen -- blood
- Prostatic Neoplasms -- blood
- Protein Kinase Inhibitors -- adverse effects
- Pyrroles -- adverse effects
- Radiography
- Sunitinib
- Taxoids -- therapeutic use
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.